Abstract

Accumulating evidence suggests that aerobic glycolysis is important for colorectal cancer (CRC) development. However, the underlying mechanisms have yet to be elucidated. B7-H3, an immunoregulatory protein, is broadly overexpressed by multiple tumor types and plays a vital role in tumor progression. In this study, we found that overexpression of B7-H3 effectively increased the rate of glucose consumption and lactate production, whereas knockdown of B7-H3 had the opposite effect. Furthermore, we showed that B7-H3 increased glucose consumption and lactate production by promoting hexokinase 2 (HK2) expression in CRC cells, and we also found that HK2 was a key mediator of B7-H3-induced CRC chemoresistance. Depletion of HK2 expression or treating cells with HK2 inhibitors could reverse the B7-H3-induced increase in aerobic glycolysis and B7-H3-endowed chemoresistance of cancer cells. Moreover, we verified a positive correlation between the expression of B7-H3 and HK2 in tumor tissues of CRC patients. Collectively, our findings suggest that B7-H3 may be a novel regulator of glucose metabolism and chemoresistance via controlling HK2 expression in CRC cells, a result that could help develop B7-H3 as a promising therapeutic target for CRC treatment.

Highlights

  • Colorectal cancer (CRC) is the third most prevalent cancer type in the world[1]

  • B7-H3 controls expression of hexokinase 2 (HK2) via STAT3 To investigate how B7-H3 regulates aerobic glycolysis in CRC, we analyzed the expression of a spectrum of key glycolysis-related genes, including Glucose transporter 1 (GLUT1), Glucose transporter 4 (GLUT4), Lactate dehydrogenase A (LDHA), Lactate dehydrogenase B (LDHB), HK2, pyruvate kinase M 2 (PKM2), hypoxiainducible factor 1α (HIF-1α) and pyruvate dehydrogenase kinase 1 (PDK1) in B7-H3overexpressing HCT116, and RKO cells with real-time quantitative PCR (RT-qPCR) (Fig. 2a, b)

  • We found that the expression level of HK2, a known mediator of aerobic glycolysis, was the most increased in both HCT116 and RKO cells with overexpression of B7-H3 (Fig. 2a, b)

Read more

Summary

Introduction

Colorectal cancer (CRC) is the third most prevalent cancer type in the world[1]. B7-H3, known as CD276, is an important immune checkpoint member of the B7-CD28 family[3]. As a type I transmembrane protein, two B7-H3 isoforms (4IgB7-H3 and 2Ig-B7-H3) have been identified; 4Ig-B7-H3 is the main isoform in humans and 2Ig-B7-H3 is the only isoform in mice[4]. Because of the lack of an identified receptor, the immunologic function of B7-H3 remains controversial, with conflicting costimulatory and coinhibitory functions[5]. B7-H3 has been reported to be a pivotal non-immunologically multifunctional protein involved in the regulation of many key cellular events. Accumulated evidence indicates that aberrant expression of B7-H3 is a common characteristic of CRC and is consistently correlated with poor patient prognosis, suggesting its emerging importance in CRC

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call